ClinicalTrials.gg
Status unknownNCT05245604Updated Feb 18, 2022

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

A Phase 3 interventional study of TJO-087 and Cyclosporine ophthalmic solution 0.05% in Dry Eye Syndrome, sponsored by Taejoon Pharmaceutical Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by Taejoon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jun 2020, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of — 5 open to participants now, 6 under way, 1 of them phase 3. Dry Eye Syndromes · Korea, Republic of.

Planned enrollment
11th of 52
182 · median 99
Started
2020
with 8 others
Phase 3
16 of 58
1 open now
Registered
39th of 58
by date
Lead sponsor
6 of 58
Taejoon Pharmaceutical Co., Ltd.

Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 52 interventional ones that give a count, is one of 9 that started in 2020, is one of 16 in phase 3, and was the 39th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.

03

Conditions studied

  • Dry Eye Syndrome

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age 20 or over
  • Patients with moderate to severe dry eye
  • Screening both eyes, the corrected visual acuity is 0.2 or more
  • Written to participate in the trial

Exclusion criteria

Exclusion Criteria:

  • Screening visits within 2 weeks who treated with topical NSAIDs/hyaluronate sodium ophthalmic solutions
  • Screening visits within 2 months the patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease)
  • Intraocular pressure(IOP)> 25 mmHg
  • Patient using or to use punctual plug within 1 months.
  • Patients with contact lens.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    TJO-087

    Drug: TJO-087

  • Active comparator
    Cyclosporine 0.05%

    Drug: Cyclosporine ophthalmic solution 0.05%

Interventions

  • DrugTJO-087

    Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily

  • DrugCyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Non-anesthetic Schirmer Test at Week 32

    The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac.

    Time frame: Baseline and Week 32

Secondary outcomes

  1. Change From Baseline in Non-anesthetic Schirmer Test at Week 8, 16, 24

    The Schirmer test without anesthesia was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac.

    Time frame: Baseline, Week 8, 16 and 24

  2. Change From Baseline in Corneal Fluorescein Staining Score at Week 8, 16, 24 and 32

    Change from Baseline in corneal staining of the worse eye using blue fluorescein staining procedure.

    Time frame: Baseline, Week 8, 16, 24 and 32

07

Study locations

1 of 1 sites recruiting
  • Hyo Myung, Kim
    Seoul, Korea, Republic of
    Recruiting
    • Hyo Myung Kim, MD, PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Aug 2022, 26 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 26 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 18, 2022
StartActual
Jun 19, 2020
Primary completionEst.
Aug 2022
CompletionEst.
Apr 2023
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05245604
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Jun 19, 2020
Primary completion
Aug 2022 (estimated)
Completion
Apr 2023 (estimated)
Last update
Feb 18, 2022

Study contacts

Sukyoung Kwon
Contact
skkwon@taejoon.co.kr
82-2-799-0184
Hyo Myung Kim, MD, PhD
principal investigator · Korea University Anam Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion